WeDaita

WeDaita | AI Drug Discovery Platform

BioMedAI From Target to Candidate — in One Platform

An end-to-end AI platform for drug discovery researchers. Identify novel targets, design protein & antibody therapeutics, and accelerate small molecule optimisation — all within a single intelligent workflow.

90%

Reduced Research Time

70%

Drug Design Cycle

2×

Clinical Trial Excution

Try BioMedAI See It in Action Book a Call

Solving Drug Discovery at Scale

Drug discovery has long been defined by decade-long timelines, billion-dollar costs, and high failure rates. WeDaita is changing that — with AI agents built to compress timelines, cut costs, and improve decision quality at every stage of the pipeline.

90%

Failure Rate

9 in 10 drug candidates fail — most due to poor target validation and inadequate early-stage evidence. WeDaita's DBRA agents surface higher-confidence targets from the start.

10–15

Years per Drug

A decade-plus of research, design, and trials before patients see results. WeDaita compresses the early discovery pipeline from years to weeks.

$2–3B

Per Drug Candidate

Billions spent per approved drug — driven by inefficiency and late-stage failures. WeDaita reduces the cost burden by cutting wasted research cycles early.

BioMedAI Platform

One Platform. Full Discovery Pipeline.

Three agent modules that cover the complete drug discovery workflow — from target to candidate.

2 Agents Live

Stage 1 — Early Research

DBRA

Deep Biomedical Research Agents

Solves the Haystack Problem — automating evidence synthesis to generate and validate novel drug targets — in hours, not months.

Deep Research on drug research
Disease-to-target hypothesis generation
Drug Target PrioritizationIn Dev
Drug RepurposingIn Dev

90%

Reduction in early research time

1 Agent Live

Stage 2 — Drug Design

ADDA

Autonomous Drug Design Agents

Bridges the Translation Gap — automating biologic and small molecule drug design to reduce preclinical failure rates.

Protein / antibody drug design
Peptide/MacrocycleIn Dev
Small molecule design & optimisationIn Dev

70%

Faster drug design cycles (projected)

Roadmap

Stage 3 — Clinical Trials

CTIA

Clinical Trial Intelligence Agents

Addresses Late-Stage Attrition — AI-assisted protocol design, predictive recruitment, and portfolio optimization.

Digital twin trial simulationRoadmap
Predictive patient recruitmentRoadmap
AI-assisted protocol designRoadmap
Portfolio optimizationRoadmap

2×

Faster clinical trial execution (vision)

See BioMedAI in Action

See how BioMedAI DBRA agents deliver trusted biomedical insights through intelligent AI agents

Plug-and-play biomedical AI via WeDaita MCP services
High-confidence insights from verified medical and clinical databases
Rapid literature review and clinical trial intelligence
Seamless agent-tool integration with zero local installation

Grounded in Primary Scientific Sources

Every insight traces back to PubMed, UniProt, ChEMBL, PDB, and 7+ other primary databases — not black-box outputs.

Built by Drug Discovery Scientists

Our team has decades of combined experience in computational biology, medicinal chemistry, and AI research.

Researcher in the Loop, Always

BioMedAI accelerates your thinking — your scientific judgement drives every key decision.

What Will You Work On Today?

Choose Your Discovery Workflow

BioMedAI adapts to where you are in the pipeline. Start from any stage.

DBRA · Live Now Deep Research on drug research

I need to explore biomedical literature for a disease or target area

DBRA agents scan 11+ biomedical databases in parallel — PubMed, UniProt, OMIM, DisGeNET and more — delivering ranked, evidence-backed insights in hours, not months.

Try DBRA

DBRA · Live Now Disease-to-target hypothesis generation

I need to identify novel drug targets for a disease

DBRA maps disease pathways and proposes high-confidence target candidates with traceable, evidence-backed reasoning — ready for experimental validation.

Try DBRA

DBRA · In Development Drug Target Prioritization

I need to rank and score a shortlist of drug targets

Coming soon — DBRA's prioritisation module will score targets by druggability, novelty, and clinical evidence strength.

Get Notified

DBRA · In Development Drug Repurposing

I need to find repositioning opportunities for existing drugs

Coming soon — DBRA's repurposing agent cross-references approved compounds against emerging disease mechanisms to surface unexpected matches.

Get Notified

ADDA · Live Now Protein / antibody drug design

I need to design a protein or antibody therapeutic

ADDA agents generate, score, and optimise therapeutic candidates — including affinity maturation and developability assessment for your target.

Try ADDA

ADDA · In Development Peptide/Macrocycle

I need to design a peptide or macrocycle drug

In development — ADDA's peptide module will generate constrained peptide scaffolds with optimised binding and cell permeability profiles.

Get Notified

ADDA · In Development Small molecule design & optimisation

I need to optimise a small molecule hit series

In development — ADDA will generate ADMET-aware analogues and scaffold hops from your initial hit using generative chemistry with property guardrails.

Get Notified